Study on the minimum effective induction dose of Esketamine in opioid-free general anesthesia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400086503

Enrollment

Unknown

Registered

2024-07-03

Start date

2024-07-03

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

experimental group:Esketamine

Eligibility

Sex/Gender

Female

Age

19 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) American Society of Anesthesiologists (ASA) grade I~III (2) Age 19~65 years old, female. (3) Understand and fully cooperate with the research.

Exclusion criteria

Exclusion criteria: (1)body mass index,BMI>30kg/m² (2) History of angina pectoris or myocardial infarction within the past 6 months (3) Patients with poorly controlled or untreated hypertension (resting systolic/diastolic blood pressure> 180/100mmHg) (4) Patients with sleep apnea or any other sleep disorder (5) Patients with liver and kidney insufficiency (6) Patients with neuropsychiatric disorders (7) Long-term alcoholics (8) Long-term use of sedative-hypnotic analgesic drugs (9) Heart rate < 50 beats/min or third-degree atrioventricular block (10) Knowingly allergic to the test drug such as dexmedetomidine or/and esketamine (11) Intraoperative change of surgical method (12) Perioperative patient data loss.

Design outcomes

Primary

Measure	Time frame
HR;MAP;PSI;	—

Countries

China

Contacts

Public ContactLi Xiaoxia

The Second Affiliated Hosipital of Chongqing Medical University

300465@hospital.edu.cn+86 133 6838 0465

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026